Treatment approaches for patients with R/R AML and the importance of preventing relapse

Alessandro Isidori, MD, PhD, Marche Nord Hospital, Pesaro, Italy, discusses treatment approaches for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML), highlighting the importance of preventing relapse with maintenance therapy. Dr Isidori further discusses the value of using genetic tests to identify mutations present at relapse, and directly targeting these mutations with agents such as ivosidenib, enasidenib, gilterinib, and quizartinib. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.